Elahere
Biological Oncology
NDC 72903-853-01
General payments
$648,142
Research payments
$3,629,318
Through program year 2023, $648,142 in general payments and $3,629,318 in research payments were reported against Elahere (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | General | $648,142 | 2,847 |
| 2023 | Research | $3,629,318 | 282 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2023.
The top 5 of 49 specialties; each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.
The top 5 of 49 states; each share is of general payments naming this product in 2023 where a state was reported.
Records
2,847 general · 282 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.